유전자 검사 시대 골수형성이상증후군의 진단과 치료
Diagnosis and Treatment of Myelodysplastic Syndrome in the Era of Genetic Testing
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Myelodysplastic syndrome (MDS) is a heterogeneous disorder with diverse prognoses influenced by cytopenias, genetic variants, and myeloblast proportions in the bone marrow. Accurate prognosis prediction and tailored treatment plans are essential. The International Prognostic Scoring System-Molecular (IPSS-M), which additionally reflects the impact of MDS-related genetic mutations to the clinical and laboratory information, is anticipated to offer superior prognostic accuracy compared to existing systems like the Revised International Prognostic Scoring System (IPSS-R). Despite its statistical complexity, its web-based calculation and ease of discussing results with patients using intuitive data sets provide notable advantages. Progress in MDS treatment, exemplified by effective anemia correction with an erythropoiesis-maturation agent in SF3B1-mutated cases and efforts to refine poor prognoses in TP53-mutated cases, reflects the evolving landscape of genetic-based interventions in MDS. Advancements in genetic diagnostic technology, combined with enhanced knowledge of the bone marrow niche, are anticipated to lead to significant improvement in MDS treatment outcomes in the future.
Abstract
Myelodysplastic syndrome (MDS) is a heterogeneous disorder with diverse prognoses influenced by cytopenias, genetic variants, and myeloblast proportions in the bone marrow. Accurate prognosis prediction and tailored treatment plans are essential. The International Prognostic Scoring System-Molecular (IPSS-M), which additionally reflects the impact of MDS-related genetic mutations to the clinical and laboratory information, is anticipated to offer superior prognostic accuracy compared to existing systems like the Revised International Prognostic Scoring System (IPSS-R). Despite its statistical complexity, its web-based calculation and ease of discussing results with patients using intuitive data sets provide notable advantages. Progress in MDS treatment, exemplified by effective anemia correction with an erythropoiesis-maturation agent in SF3B1-mutated cases and efforts to refine poor prognoses in TP53-mutated cases, reflects the evolving landscape of genetic-based interventions in MDS. Advancements in genetic diagnostic technology, combined with enhanced knowledge of the bone marrow niche, are anticipated to lead to significant improvement in MDS treatment outcomes in the future.
참고문헌 (25)
- Khoury JD, "The 5th edition of the World Health Organization classification of haematolymphoid tumours : myeloid and histiocytic", dendritic neoplasms, 2022, pp.36, 1703~1719
- Greenberg PL, "Revised international prognostic scoring system for myelodysplastic syndromes", Blood, 120, pp.2454~2465 (2012)
- Greenberg P, "International scoring system for evaluating prognosis in myelodysplastic syndromes", Blood, 89, pp.2079~2088 (1997)
- Haferlach T, "Landscape of genetic lesions in 944 patients with myelodysplastic syndromes", Leukemia, 28, pp.241~247 (2014)
- Ogawa S, "Genetics of MDS", Blood, 133, pp.1049~1059 (2019)
- Bernard E, "Molecular international prognostic scoring system for myelodysplastic syndromes", NEJM Evid, 1, pp.2200008~ (2022)
- List A, "Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion", N Engl J Med, 355, pp.1456~1465 (2006)
- Aguirre LE, "Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes", Leukemia, 37, pp.1530~1539 (2023)
- Kewan T, "Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes", Blood, 141, pp.1768~1772 (2023)
- Sauta E, "Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes", J Clin Oncol, 41, pp.2827~2842 (2023)
- Yang T, "Comparison of the prognostic predictive value of molecular international prognostic scoring system and revised international prognostic scoring system in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms", Am J Hematol, 98, pp.E391~E394 (2023)
- Bejar R, "How can we incorporate molecular data into the IPSS?", Best Pract Res Clin Haematol, 35, pp.101410~ (2022)
- Arber DA, "International consensus classification of myeloid neoplasms and acute leukemias : integrating morphologic, clinical, and genomic data", Blood, 140, pp.1200~1228 (2022)
- Carraway HE, "Therapy for lower-risk MDS", Hematology Am Soc Hematol Educ Program, 2020, pp.426~433 (2020)
- Fenaux P, "Luspatercept in patients with lower-risk myelodysplastic syndromes", N Engl J Med, 382, pp.140~151 (2020)
- Suragani RN, "Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia", Blood, 123, pp.3864~3872 (2014)
- Platzbecker U, "Long-term efficacy and safety of luspatercept for anemia treatment in patients with lower-risk myelodysplastic syndromes : the phase II PACE-MDS study", J Clin Oncol, 40, pp.3800~3807 (2022)
- De La Garza A, "The splicing factor Sf3b1 regulates erythroid maturation and proliferation via TGFβ signaling in zebrafish", Blood Adv, 3, pp.2093~2104 (2019)
- Platzbecker U, "Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lowerrisk myelodysplastic syndromes(COMMANDS) : interim analysis of a phase 3, open-label, randomised controlled trial", Lancet, 402, pp.373~385 (2023)
- Campo E, "TP53 aberrations in chronic lymphocytic leukemia : an overview of the clinical implications of improved diagnostics", Haematologica, 103, pp.1956~1968 (2018)
- Bernard E, "Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes", Nat Med, 26, pp.1549~1556 (2020)
- Grob T, "Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome", Blood, 139, pp.2347~2354 (2022)
- de Witte T, "Allogeneic hematopoietic stem cell transplantation for MDS and CMML : recommendations from an international expert panel", Blood, 129, pp.1753~1762 (2017)
- da Silva-Coelho P, "Clonal evolution in myelodysplastic syndromes", Nat Commun, 8, pp.15099~ (2017)
- Cogle CR, "Bone marrow niche in the myelodysplastic syndromes", Leuk Res, 39, pp.1020~1027 (2015)